Fig. 3: CTPI-2 normalizes glucose tolerance and insulin sensitivity. | Cell Death & Differentiation

Fig. 3: CTPI-2 normalizes glucose tolerance and insulin sensitivity.

From: Inhibition of the mitochondrial citrate carrier, Slc25a1, reverts steatosis, glucose intolerance, and inflammation in preclinical models of NAFLD/NASH

Fig. 3

a Fasting glucose levels in control diet (C, white bars), HFD+Vehicle (V, grey bars), or HFD+CTPI-2 (T, red bars) mice (n = 3–6). b Insulin levels (in μg/ml) of animals treated with CTPI-2 for approximately 11 weeks (n = 2–3). c Glucose tolerance test performed at the indicated time points of CTPI-2 treatment (n = 3–4). Grey lines indicate control diet; black lines indicate HFD+vehicle; and red lines indicate HFD+CTPI-2. d Insulin tolerance test in the indicated mice groups. e Expression levels of Slc25a1 (shown at two different exposure times, Exp.1 and Exp.2) in the indicated organs and treatment conditions. f Expression levels of Slc25a1 in the visceral adipose tissue of mice fed with chow (C), high-glucose (HG), or low-glucose (LG) diets (see “Materials and methods” for diet composition). g Fasting glucose levels in mice fed as indicated (n = 4–6). *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.

Back to article page